| Title: | Lipoprotein (a) and risk of clinical outcomes including chronic kidney disease, cardiovascular diseases and cancers among different glycemic status: an interactive and prospective analysis |
| Lead Institution: | Ruijin Hospital |
| Principal investigator: | Professor Min Xu |
Application 64754
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Strong evidence in epidemiological studies and clinical trials have verified that high level of blood lipoprotein (a) (Lp[a]) levels, one of the important components of blood lipids, were associated with a higher risk of cardiovascular disease (CVD), and an indication of premature atherosclerotic cardiovascular disease (ASCVD). Interestingly, previous studies demonstrated an inverse relationship between Lp(a) and type 2 diabetes (T2D). A high level of blood Lp[a] associates a lower risk of developing T2D. It is known that T2D is a well-established risk factor for CVD. The mechanism of this contradictory association of Lp(a) with CVD and T2D is remains elucidated. Therefore, it is important to understand the attributes of Lp(a)-lowering the cardiovascular risk and consequences of T2D. However, rare studies and no recommendation investigated how to specifically manage high Lp(a) concentration among populations with different status of glucose metabolism (T2D, prediabetes, and normal glucose regulation). In this project, we aimed to - detangle the association between Lp(a) and the important health outcomes, including CVD, chronic kidney diseases (CKD), and cancers among populations stratified by glycemic status. - construct the genetic risk scores (GRS) of Lp(a) and T2D, respectively, to investigate the interactive and combined effect on CVD, CKD, and cancer risk. - detect the causal relationship of Lp(a) with CVD or T2D risk using a mendelian randomization analysis. We expect a project duration of 36 months. The analysis will provide strong evidence to instruct the better lipids and glucose management while in the prevention and treatment of CVD, CKD, and cancer patients.4 Publications
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 9293 | Evaluation of the Effect of Sodium-Glucose Cotransporter 2 Inhibition on Fracture Risk: Evidence From Mendelian Randomization and Genetic Association Study | Huajie Dai (+20) | 2023 | Journal of Bone and Mineral Research |
| 8367 | Roles of gut microbiota in atrial fibrillation: insights from Mendelian randomization analysis and genetic data from over 430,000 cohort study participants | Huajie Dai (+18) | 2023 | Cardiovascular Diabetology |
| 8393 | Sex-specific causality of MRI-derived body compositions on glycaemic traits: Mendelian randomization and observational study | Yijie Zhu (+16) | 2023 | Diabetes Obesity and Metabolism |
| 9407 | The effect of metformin on urate metabolism: Findings from observational and Mendelian randomization analyses | Huajie Dai (+14) | 2023 | Diabetes Obesity and Metabolism |
Enabling scientific discoveries that improve human health